Acute lymphocytic leukaemia

Active Ingredient: Daunorubicin

Indication for Daunorubicin

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

As an antimitotic and cytotoxic for the induction of remissions in acute lymphocytic and myelogenous leukaemias.

Daunorubicin, as part of combination regimen, is indicated for the treatment of acute lymphocytic leukemia and acute myeloid leukemia in children.

For this indication, competent medicine agencies globally authorize below treatments:



Dosage regimens

Intravenous, between 40 milligrams daunorubicin per square meter of body surface and 60 milligrams daunorubicin per square meter of body surface, 1 to 3 doses in total.

Detailed description

40-60mg/m² on alternate days for a course of up to three infusions.

45mg/m²/day is the recommended dose.


Use with care in patients with inadequate bone marrow reserves. A dosage reduction of up to 50% is recommended.

300 mg/m²


Dosage regimens

Intravenous, 300 milligrams daunorubicin per square meter of body surface, once every 3 to 6 weeks.

Detailed description

Cerubidin dose for children (over 2 years) is usually calculated based on the body surface area and adjusted to meet individual requirements of each patient, on the basis of clinical response and the patient’s haematological status. Courses may be repeated after 3 to 6 weeks.

Current specialized protocols and guidelines should be consulted for appropriate treatment regimen.

For children over 2 years the maximum cumulative dose is 300 mg/m².

For children under 2 years of age (or below 0.5 m² body surface area), the maximum cumulative dose is 10 mg/kg.

Active ingredient


Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. Daunorubicin may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction.

Read more about Daunorubicin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.